• Firefly Luciferase mRNA: Assay Workflow Guide

  2026-08-30

  Build more reproducible transfection, gene expression, and cell viability workflows with an ARCA-capped, modified reporter transcript. Learn how to connect bench-scale luminescence controls with LNP delivery and in vivo imaging decisions without confusing reporter output with biological effect.

• PreScission Protease (PSP): Tag Cleavage Guide

  2026-08-29

  PreScission Protease (PSP), SKU K1101, provides sequence-specific removal of fusion tags from recombinant proteins during purification. It is intended for substrates containing the defined HRV 3C protease cleavage site and is not a general-purpose protease for proteins lacking that sequence. The workflow should be performed under cold, compatible buffer conditions, with cleavage time and enzyme loading established empirically for each fusion construct.

• Y-27632 ROCK Inhibitor Workflow for Gastruloids

  2026-08-28

  Y-27632 enables reversible ROCK1/2 inhibition in workflows that connect cytoskeletal remodeling with gastruloid formation, imaging, and single-construct profiling. This guide translates a microraft-array study of euploid, aneuploid, and mosaic human pluripotent stem cell models into practical dosing, assay-design, and troubleshooting decisions.

• PPARγ, Macrophage Polarization, and DSS Colitis

  2026-08-28

  The reference study identifies PPARγ activation as a regulator of M1/M2 macrophage balance in dextran sulfate sodium-induced intestinal inflammation, linking this effect to opposing STAT-1 and STAT-6 phosphorylation. Its combined cell and mouse experiments connect macrophage phenotype, epithelial barrier integrity, and clinical disease features, while also defining important limits for translating findings beyond acute experimental colitis.

• DMG-PEG2000-NH2 in LNP Linker Workflows

  2026-08-27

  DMG-PEG2000-NH2 is an NH2-PEG derivative for controlled amide coupling, lipid nanoparticle (LNP) formulation, and surface-functionalized liposome development. This practical guide connects reagent handling, conjugation design, siRNA encapsulation considerations, and assay-based troubleshooting without overstating evidence from unrelated disease-model studies.

• Anlotinib Hydrochloride: An Assay-First Framework

  2026-08-27

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor that enables a more rigorous way to connect receptor phosphorylation with angiogenic phenotypes. This assay-first framework shows how to distinguish VEGFR2, PDGFRβ, and FGFR1 effects from downstream ERK convergence in cancer research.

• Thiamet G: From O-GlcNAc to Assay Logic

  2026-08-26

  Thiamet G is a selective O-GlcNAcase inhibitor for controlling protein O-GlcNAcylation in cellular and animal models. This guide connects its pharmacology with Wnt-driven osteogenesis and provides a framework for distinguishing target engagement from downstream phenotypes.

• Abiraterone Acetate in 3D Prostate Models

  2026-08-26

  Abiraterone acetate offers translational researchers a mechanistically defined CYP17 inhibitor for interrogating androgen biosynthesis in patient-derived prostate cancer models. By combining compound rigor with three-dimensional spheroid biology, researchers can distinguish target engagement from model-specific resistance and build more informative preclinical workflows.

• Cy3 NHS ester (non-sulfonated): Practical Guide

  2026-08-25

  Cy3 NHS ester (non-sulfonated) supports covalent orange-fluorescent labeling of accessible amino groups on proteins, peptides, and amino-modified oligonucleotides. It is suited to workflows that can tolerate DMSO or DMF, but should not be selected for water-only labeling or biomolecules that are highly sensitive to organic co-solvents.

• EAGLE-2 and EAGLE-3: Gepotidacin in UTI

  2026-08-25

  The EAGLE-2 and EAGLE-3 phase 3 trials showed that oral gepotidacin was non-inferior to nitrofurantoin for uncomplicated urinary tract infection and superior in one of the two studies. Their principal innovation was clinical evaluation of a first-in-class antibiotic that targets bacterial type II topoisomerases through a distinct binding site, offering a potential option when resistance limits established therapies.

• Aloin A and B Inhibit SARS-CoV-2 PLpro In Vitro

  2026-08-24

  The reference study identified aloin A and aloin B as selective in vitro inhibitors of both the proteolytic and deubiquitinating activities of SARS-CoV-2 papain-like protease (PLpro), while sparing 3CLpro. Its paired enzyme assays, structural modeling, and molecular dynamics simulations provide a mechanistic framework for evaluating oral-rinse ingredients, but the findings do not establish clinical antiviral efficacy.

• HyperScribe T7 High Yield Cy5 RNA Kit

  2026-08-24

  The HyperScribe T7 High Yield Cy5 RNA Labeling Kit enables customizable fluorescent RNA probe synthesis for studying TREM2 biology. This guide connects Cy5-UTP incorporation with assay design decisions in macrophage efferocytosis, tissue imaging, and transcript validation.

• Carbenoxolone disodium: Protocol and QC Guide

  2026-08-23

  Carbenoxolone disodium is an 11β-hydroxysteroid dehydrogenase inhibitor for mechanistic studies of glucocorticoid access, corticosterone metabolism, and gap junction communication in cell- and tissue-based systems. It is best used with orthogonal controls and should not be treated as a selective probe for in vivo efficacy studies or assays where off-target effects cannot be controlled.

• RNA Pol II Degradation Activates Cell Death

  2026-08-22

  The preprint argues that RNA polymerase II degradation can activate cell death through a mechanism that is not simply a consequence of transcriptional shutdown. Its experimental logic separates loss of transcription from loss of the Pol II protein pool, providing a framework for interpreting cytotoxicity in transcription-targeting and cancer biology research.

• JAK Inhibitors and Endothelial Cardiovascular Effects

  2026-08-22

  A 2025 ACR Open Rheumatology study compared six JAK inhibitors in cytokine-stimulated human endothelial cells and found that reducing IL-6 did not uniformly normalize adhesion, coagulation, or apoptosis responses. The findings support dose- and inhibitor-specific interpretation of vascular effects, with important implications for inflammatory disorder research and cardiovascular risk models.

8101 records 2/541 page Previous Next 12345 下5页 Last page